CME Information
Provider Statement: This continuing medical education activity is provided by 
.
Support Statement: This activity is supported by an educational grant from Sanofi Genzyme.
Target Audience: The intended audience for this activity is neurologists and other health care professionals involved in the treatment of patients with relapsing-remitting MS (RRMS).
Learning Objectives: Upon successful completion of this educational activity, participants should be better able to:
- Apply relapse and disability outcomes for induction therapy vs. escalation therapy in the treatment of patients with RRMS.
- Evaluate efficacy and safety data for oral agents used in the treatment of patients with RRMS.
- Incorporate strategies for monitoring patients for response, safety, tolerability, and adherence to prescribed RRMS therapies.
Activity Chair:
Patricia K. Coyle, MD, FAAN, FANA
Professor and Vice Chair (Clinical Affairs)
Department of Neurology
Director
Multiple Sclerosis Comprehensive Care Center
Stony Brook University Medical Center
Stony Brook, NY
Faculty:
Bruce A. Cohen, MD, FAAN, FANA, FACP
Professor of Neurology
Northwestern University
Feinberg School of Medicine
Director
Northwestern Comprehensive Multiple Sclerosis Program
Chicago, IL
Clyde E. Markowitz, MD
Associate Professor of Neurology
Director, Multiple Sclerosis Center
Hospital of the University of Pennsylvania
Perelman School of Medicine
Philadelphia, PA
Reviewers:
Brian M. Shepler, PharmD
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP (Recertification review on 3/22/2019)
Disclosures:
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.
The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.
Activity Chair and Faculty report the following relationships which are accurate at the time of original content release (3/22/2018):
Bruce A. Cohen, MD, FAAN, FANA, FACP
Consulting Fee: EMD Serono, Mylan, Novartis
Contracted Research (Paid to Institution): Genentech/HoffmanLa Roche, MedDay, Novartis
Patricia K. Coyle, MD, FAAN, FANA
Consulting Fee: Accordant, Acorda, Bayer, Biogen, Celgene, Genentech/Roche, Genzyme/Sanofi, Novartis, Serono, Teva
Contracted Research: Actelion, Alkermes, Genentech/Roche, MedDay, NINDS, Novartis
Clyde E. Markowitz, MD
Consulting Fee: Bayer, Biogen, Celgene, EMD Serono, Novartis, Roche/Genentech, Sanofi/Genzyme, Teva
Reviewers report the following relationship(s):
Brian M. Shepler, PharmD
No relevant financial relationships to disclose.
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage:
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.
Accreditation:
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation:
Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity was originally approved for 1 year from the date of original release, March 28, 2018 to March 27, 2019. It has since been recertified for an additional year and will now expire on March 27, 2020.
How to Participate in this Activity and Obtain CME Credit:
To participate in this CME activity, you must read the objectives, answer the pretest question, watch the presentation, and complete the CME posttest and the evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 out of 3 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Copyright Statement:
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2018 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at cme@vindicoCME.com